Trileptal and Valcyte drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Trileptal (oxcarbazepine) and Valcyte (valganciclovir hydrochloride). Common drug interactions include abdominal pain upper among females and hyponatraemia among males.

The phase IV clinical study analyzes what interactions people have when they take Trileptal and Valcyte. It is created by eHealthMe based on reports of 16 people who take the same drugs from the FDA, and is updated regularly.

What is Trileptal?

Trileptal has active ingredients of oxcarbazepine. It is often used in bipolar disorder. eHealthMe is studying from 23,558 Trileptal users. Check the latest studies of Trileptal.

What is Valcyte?

Valcyte has active ingredients of valganciclovir hydrochloride. It is often used in cmv - immunocompromised host. eHealthMe is studying from 6,409 Valcyte users. Check the latest studies of Valcyte.



On Aug, 08, 2026

16 people who take Trileptal and Valcyte together, and have interactions are studied.

Trileptal and Valcyte drug interactions.

What are the common drug interactions of Trileptal and Valcyte, by gender? *:

female:

  1. Abdominal pain upper
  2. Constipation
  3. Flatulence (flatus expelled through the anus)
  4. Functional gastrointestinal disorder (functional problem in separate organs of gastrointestinal system)
  5. Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
  6. Leukopenia (less number of white blood cells in blood)
  7. Somnolence (a state of near-sleep, a strong desire for sleep)
  8. Weight decreased

male:

  1. Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)
  2. Hypoaldosteronism (decreased levels of the hormone aldosterone)
  3. General physical health deterioration (weak health status)
  4. Grand mal convulsion (a type of generalized seizure that affects the entire brain)
  5. Heart rate increased
  6. Hypertrichosis (hair growth on the body in an amount considered abnormal)
  7. Hypokalaemia (low potassium)
  8. Immunosuppressant drug level increased
  9. Leukopenia (less number of white blood cells in blood)
  10. Respiratory arrest (cessation of normal respiration due to failure of the lungs to function effectively)

What are the common drug interactions of Trileptal and Valcyte, by age (0-1 to 60+)? *:

0-1:

  1. Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)
  2. Hypoaldosteronism (decreased levels of the hormone aldosterone)
  3. Electrolyte imbalance
  4. Cardio-respiratory arrest (sudden dysfunction of heart and lungs)
  5. Partial seizures (seizures which affect only a part of the brain at onset)
  6. Hyperkalaemia (damage to or disease of the kidney)
  7. Immunosuppressant drug level increased
  8. Respiratory arrest (cessation of normal respiration due to failure of the lungs to function effectively)

2-9:

  1. Electrolyte imbalance
  2. Metabolic acidosis (body produces too much acid, or when the kidneys are not removing enough acid from the body)
  3. Erythema (redness of the skin)
  4. General physical health deterioration (weak health status)
  5. Grand mal convulsion (a type of generalized seizure that affects the entire brain)
  6. Heart rate increased
  7. Hypertrichosis (hair growth on the body in an amount considered abnormal)
  8. Hypokalaemia (low potassium)
  9. Hyponatraemia (abnormally low level of sodium in the blood; associated with dehydration)
  10. Leukopenia (less number of white blood cells in blood)

10-19:

n/a

20-29:

n/a

30-39:

  1. Abdominal pain upper
  2. Constipation
  3. Flatulence (flatus expelled through the anus)
  4. Functional gastrointestinal disorder (functional problem in separate organs of gastrointestinal system)
  5. Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
  6. Leukopenia (less number of white blood cells in blood)
  7. Somnolence (a state of near-sleep, a strong desire for sleep)
  8. Weight decreased

40-49:

n/a

50-59:

n/a

60+:

n/a

What are the existing conditions these people have? *

  1. Epilepsy (common and diverse set of chronic neurological disorders characterized by seizures): 7 people, 43.75%
  2. Immunodeficiency Disorders: 6 people, 37.50%
  3. Convulsion (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body): 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Trileptal and Valcyte?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Trileptal and Valcyte:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Trileptal:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Valcyte:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Trileptal and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Valcyte and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on oxcarbazepine and valganciclovir hydrochloride (the active ingredients of Trileptal and Valcyte, respectively), and Trileptal and Valcyte (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: